Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

316
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

324
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

537
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
537

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial.

EClinicalMedicine·2026
Same author

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Evaluation of drug-drug interactions associated with metamizole in clinical practice.

Expert review of clinical pharmacology·2026
Same author

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.

International journal of cancer·2026
Same author

Mapping drug-drug interactions in pharmacokinetic boosting of olaparib.

Cancer chemotherapy and pharmacology·2026
Same author

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous-venous extracorporeal membrane oxygenation (VV-ECMO): A case report.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Mar 1, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

4.4K

Does Weight Impact Anidulafungin Pharmacokinetics?

Vincent J Lempers1,2, Anne van Rongen3,4, Eric P van Dongen5

  • 1Department of Pharmacy, Radboud University Medical Center, 864, PO Box 9101 HB, Nijmegen, 6500, The Netherlands.

Clinical Pharmacokinetics
|May 5, 2016
PubMed
Summary
This summary is machine-generated.

Anidulafungin exposure is 32.5% lower in morbidly obese patients. This suggests that higher anidulafungin doses may be necessary for obese individuals to achieve therapeutic drug levels.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K
Examination of Host Phenotypes in Gambusia affinis Following Antibiotic Treatment
09:25

Examination of Host Phenotypes in Gambusia affinis Following Antibiotic Treatment

Published on: February 22, 2017

8.0K

Related Experiment Videos

Last Updated: Mar 1, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

4.4K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K
Examination of Host Phenotypes in Gambusia affinis Following Antibiotic Treatment
09:25

Examination of Host Phenotypes in Gambusia affinis Following Antibiotic Treatment

Published on: February 22, 2017

8.0K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Obesity Medicine

Background:

  • Bodyweight significantly impacts drug exposure.
  • Limited pharmacokinetic data exists for anidulafungin in obese populations.
  • Obesity presents unique challenges in drug dosing and efficacy.

Purpose of the Study:

  • To investigate anidulafungin pharmacokinetics in morbidly obese individuals.
  • To compare anidulafungin exposure in obese versus general patient populations.
  • To inform potential dose adjustments for anidulafungin in obesity.

Main Methods:

  • A single 100-mg dose of anidulafungin was administered.
  • Pharmacokinetic parameters were assessed in eight morbidly obese subjects (BMI >40 kg/m²).
  • Anidulafungin exposure levels were compared to established data from the general patient population.

Main Results:

  • Anidulafungin exposure was, on average, 32.5% lower in morbidly obese subjects.
  • This reduction in exposure suggests altered drug metabolism or distribution in obesity.
  • Individual variability in exposure was observed, necessitating further investigation.

Conclusions:

  • Current anidulafungin dosing may be insufficient for morbidly obese patients.
  • Higher anidulafungin doses might be required to achieve target exposure levels in this population.
  • Further clinical studies are warranted to establish optimal dosing guidelines for anidulafungin in obese patients.